Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Ruth Plummer

Newcastle AuthorsTitleYearFull text
Dr Christopher Bacon
Dr George Petrides
Dr Nicola Leech
Dr Fiona Jenkinson
Professor Ruth Plummer
et al.
A case of malignant hyperlactaemic acidosis appearing on treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.2020
Professor Ruth Plummer
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial2020
Professor Ruth Plummer
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma2020
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine2019
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Professor Ruth Plummer
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial2019
Dr Simon Findlay
Dr Jason Gill
Professor Ruth Plummer
Carol De Santis
Dr Chris Plummer
et al.
Chronic cardiovascular toxicity in the older oncology patient population2019
Dr Stamatina Verykiou
Michael Alexander
Dr Noel Edwards
Professor Ruth Plummer
Dr Bill Chaudhry
et al.
Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma2019
Professor Ruth Plummer
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial2019
Professor Ruth Plummer
Professor Steve Wedge
Professor Gareth Veal
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours2018